secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001493152-23-009837
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics reports Q4 revenue $4.0M, FY revenue $16.0M; appliance sales up 21% in Q4
--------------------------------------------------------------------------------

- Q4 2022 revenue $4.0M vs $4.4M YoY; full-year revenue $16.0M vs $16.9M; $2.5M revenue deferred under ASC 606.
- Q4 appliance arches sold 2,938 (+21% YoY); full-year 12,281 (+8% YoY).
- Gross margin 60% in Q4 (vs 71% YoY) and 63% for FY (vs 75% YoY) due to higher costs and new incentives.
- Cash $3.5M at Dec 31, 2022; raised ~$7.4M net in Jan 2023 private placement.
- Received FDA 510(k) clearance for DNA appliance for mild-to-moderate OSA; acquired patents from Advanced Facialdontics for TMD/Bruxism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/0001493152-23-009837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer